Mereo BioPharma Group’s (MREO) Market Perform Rating Reaffirmed at Lifesci Capital

Lifesci Capital reissued their market perform rating on shares of Mereo BioPharma Group (NASDAQ:MREO) in a report published on Monday morning,Benzinga reports.

Several other research analysts have also commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Mereo BioPharma Group in a report on Monday. BTIG Research cut their price target on shares of Mereo BioPharma Group from $6.00 to $1.00 and set a “buy” rating for the company in a research note on Monday. Zacks Research raised shares of Mereo BioPharma Group from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price objective on shares of Mereo BioPharma Group in a report on Monday, December 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Mereo BioPharma Group in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $4.40.

Mereo BioPharma Group Stock Performance

Mereo BioPharma Group stock opened at $0.29 on Monday. Mereo BioPharma Group has a fifty-two week low of $0.20 and a fifty-two week high of $3.84. The stock has a market cap of $46.15 million, a P/E ratio of -4.83 and a beta of 0.45. The firm’s fifty day moving average price is $1.94 and its 200-day moving average price is $1.98.

Mereo BioPharma Group (NASDAQ:MREO) last posted its earnings results on Monday, November 10th. The company reported ($0.01) EPS for the quarter. Sell-side analysts predict that Mereo BioPharma Group will post -0.03 earnings per share for the current year.

Institutional Trading of Mereo BioPharma Group

Several hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. boosted its position in Mereo BioPharma Group by 0.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,125,920 shares of the company’s stock valued at $4,783,000 after buying an additional 6,068 shares during the period. Significant Wealth Partners LLC lifted its stake in shares of Mereo BioPharma Group by 61.7% in the 2nd quarter. Significant Wealth Partners LLC now owns 22,261 shares of the company’s stock valued at $60,000 after acquiring an additional 8,490 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in Mereo BioPharma Group by 45.4% during the 3rd quarter. Squarepoint Ops LLC now owns 30,055 shares of the company’s stock valued at $62,000 after acquiring an additional 9,387 shares during the period. Marex Group plc purchased a new stake in Mereo BioPharma Group during the 2nd quarter valued at about $27,000. Finally, Avanza Fonder AB grew its position in Mereo BioPharma Group by 36.0% during the 2nd quarter. Avanza Fonder AB now owns 38,235 shares of the company’s stock worth $104,000 after acquiring an additional 10,114 shares during the last quarter. 62.83% of the stock is owned by institutional investors.

Mereo BioPharma Group News Roundup

Here are the key news stories impacting Mereo BioPharma Group this week:

• Positive Sentiment: Mereo said it is implementing cost controls and provided program updates that may reduce cash burn and extend runway while the company assesses next steps. Article Title
• Positive Sentiment: Some analysts (BTIG) maintained a constructive stance by keeping a “buy” rating despite slashing their price target, which could suggest selective investor support if management outlines a credible recovery plan. Article Title
• Neutral Sentiment: Trading in MREO was temporarily halted for “news pending,” a routine market-protection step that concentrated selling once the halt lifted. (Trading halt reported 08:25 AM on 12/29.)
• Neutral Sentiment: LifeSci Capital had earlier reaffirmed a “market perform” rating, reflecting caution prior to the trial results and signaling mixed analyst views. Article Title
• Negative Sentiment: Mereo announced that both Phase 3 ORBIT and COSMIC failed to achieve their primary endpoint of reducing annualized clinical fracture rate versus placebo or bisphosphonates — a direct hit to the commercial outlook for setrusumab. Article Title
• Negative Sentiment: Following the trial news, LifeSci Capital officially downgraded Mereo, adding analyst pressure and reducing investor confidence. Article Title
• Negative Sentiment: Broad market coverage highlights the stock plunge and investor losses; commentary and sell-side note circulation (AAII, Investing.com, Benzinga) have amplified selling pressure. Article Title
• Negative Sentiment: BTIG cut its price target sharply (from $6.00 to $1.00), signaling much lower near-term valuation expectations despite retaining a buy rating; that PT cut likely weighs on sentiment. Article Title

About Mereo BioPharma Group

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.